Double-Blind Study of the Therapeutic Efficacy of Zinc Picolinate in Taste Disorder: Preliminary Report

doi:10.1007/978-4-431-68355-1_239

Paper

Double-Blind Study of the Therapeutic Efficacy of Zinc Picolinate in Taste Disorder: Preliminary Report

Published 1994 · F. Sakai, S. Yoshida, S. Endo

0

Citations

0

Influential Citations

Full text Semantic Scholar

Abstract

In an earlier study, we investigated the therapeutic efficacy of orally given zinc gluconate in taste disorders in a double-blind study [1]. No significant difference was detected between zinc gluconate and placebo. However, a significant superiority of zinc gluconate to placebo was observed in patients with idiopathic and zinc-deficient taste disorders. Here, we studied the therapeutic efficacy of zinc in patients with taste disorders limited to idiopathic and zinc-deficient groups. The test drug was zinc picolinate. We used this drug since Barrie et al. [2] reported that picolinic acid promoted the absorption of zinc in humans, and that it was superior to gluconate. The efficacy was assessed in a double-blind study; the degree of improvement in taste examination, and subjective symptoms, were evaluated.

Study Snapshot

Key takeawayZinc picolinate shows potential therapeutic efficacy in patients with idiopathic and zinc-deficient taste disorders, improving taste examination and subjective symptoms.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Double-Blind Study of the Therapeutic Efficacy of Zinc Picolinate in Taste Disorder: Preliminary Report

References

Citations